ClinicalTrials.gg
CompletedNCT00694707Updated Jun 12, 2019Results posted

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

A Phase 2 interventional study of Placebo and Cariprazine in Schizophrenia, sponsored by Forest Laboratories. Completed at 65 sites in 5 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-06-12.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
732
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
3rd of 23
732 · median 129
Started
2008
with 1 other
Phase 2
4 of 23
none open now
Registered
2nd of 23
by date
Lead sponsor
8 of 23
Forest Laboratories

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 3rd largest by enrollment, is one of 2 that started in 2008, is one of 4 in phase 2, and was the 2nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 60 years of age.
  • Meets , 4th Edition (DSM-IV) criteria for schizophrenia (paranoid type, disorganized type, catatonic type, or undifferentiated type) based on a Structured Clinical Interview for DSM-IV (SCID).
  • Total Positive and Negative Syndrome Scale (PANSS) score ≥ 80 and ≤ 120.
  • Diagnosis of schizophrenia for at least 1 year.

Exclusion criteria

Exclusion Criteria:

  • Abnormalities on physical examination or abnormal vital signs, , or clinical laboratory values.
  • First episode of psychosis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
732 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo orally once a day for 6 weeks.

    Drug: Placebo

  • Experimental
    Cariprazine 1.5 mg

    Participants received cariprazine 1.5 mg orally once a day for 6 weeks.

    Drug: Cariprazine

  • Experimental
    Cariprazine 3.0 mg

    Participants received cariprazine 3.0 mg orally once a day for 6 weeks.

    Drug: Cariprazine

  • Experimental
    Cariprazine 4.5 mg

    Participants received cariprazine 4.5 mg orally once a day for 6 weeks.

    Drug: Cariprazine

  • Active comparator
    Risperidone 4.0 mg

    Participants received risperidone 4.0 mg orally once a day for 6 weeks.

    Drug: Risperidone

Interventions

  • DrugPlacebo

    Placebo was supplied in capsules.

  • Cariprazine was supplied in capsules

    Also known as: RGH-188

  • Risperidone was supplied in capsules

    Also known as: Risperdal

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in the PANSS Total Score

    The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change From Baseline to Week 6 in the CGI-S Score

    The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.

    Time frame: Baseline to Week 6

07

Results

Posted Jun 12, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mg
Started151145147148141
Completed79909698101
Not completed7255515040
Withdrew: Did not receive treatment00111
Withdrew: Adverse event221481213
Withdrew: Insufficient therapeutic response3318171510
Withdrew: Protocol violation12131
Withdrew: Withdrawal of consent1418221615
Withdrew: Lost to follow-up01200
Withdrew: Jeopardizing parole status10000
Withdrew: Death in the family10000
Withdrew: Arrest by police01000
Withdrew: Administrative reasons01020
Withdrew: Notification of past head injury00010

Outcome measures

PrimaryChange From Baseline to Week 6 in the PANSS Total Score

The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.

Time frame:
Baseline to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline to Week 6 in the PANSS Total Score
Units on a scalePlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mg
Baseline97.3 ± 0.897.1 ± 0.897.2 ± 0.796.7 ± 0.898.1 ± 0.8
Change at Week 6-9.5 ± 1.6-17.3 ± 1.7-18.7 ± 1.8-20.2 ± 1.6-25.3 ± 1.7
Statistical analysis
  • Placebo vs Cariprazine 1.5 mg · ANCOVA · p = 0.0005 · Least squares mean difference: -7.5 · 95% CI -11.8 to -3.3The analysis of covariance (ANCOVA) included treatment group and study center as factors and the Baseline PANSS total score as the covariate.
  • Placebo vs Cariprazine 3.0 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -8.8 · 95% CI -13.1 to -4.6The analysis of covariance (ANCOVA) included treatment group and study center as factors and the Baseline PANSS total score as the covariate.
  • Placebo vs Cariprazine 4.5 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -10.4 · 95% CI -14.6 to -6.2The analysis of covariance (ANCOVA) included treatment group and study center as factors and the Baseline PANSS total score as the covariate.
  • Placebo vs Risperidone 4.0 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -15.0 · 95% CI -19.4 to -10.8The analysis of covariance (ANCOVA) included treatment group and study center as factors and the Baseline PANSS total score as the covariate.
SecondaryChange From Baseline to Week 6 in the CGI-S Score

The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.

Time frame:
Baseline to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline to Week 6 in the CGI-S Score
Units on a scalePlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mg
Baseline4.9 ± 0.14.7 ± 0.14.9 ± 0.14.8 ± 0.14.8 ± 0.1
Change at Week 6-0.6 ± 0.1-0.9 ± 0.1-1.1 ± 0.1-1.2 ± 0.1-1.4 ± 0.1
Statistical analysis
  • Placebo vs Cariprazine 1.5 mg · ANCOVA · p = 0.0040 · Least squares mean difference: -0.4 · 95% CI -0.6 to -0.1The analysis of covariance (ANCOVA) included treatment group and study center as factors and the Baseline CGI-S score as the covariate.
  • Placebo vs Cariprazine 3.0 mg · ANCOVA · p = 0.0003 · Least squares mean difference: -0.5 · 95% CI -0.7 to -0.2The analysis of covariance (ANCOVA) included treatment group and study center as factors and the Baseline CGI-S score as the covariate.
  • Placebo vs Cariprazine 4.5 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -0.6 · 95% CI -0.9 to -0.4The analysis of covariance (ANCOVA) included treatment group and study center as factors and the Baseline CGI-S score as the covariate.
  • Placebo vs Risperidone 4.0 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -0.8 · 95% CI -1.1 to -0.6The analysis of covariance (ANCOVA) included treatment group and study center as factors and the Baseline CGI-S score as the covariate.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/151 (0%)7/151 (4.6%)67/151 (44.4%)
Cariprazine 1.5 mg0/145 (0%)5/145 (3.4%)73/145 (50.3%)
Cariprazine 3.0 mg0/146 (0%)0/146 (0%)74/146 (50.7%)
Cariprazine 4.5 mg0/147 (0%)4/147 (2.7%)87/147 (59.2%)
Risperidone 4.0 mg0/140 (0%)3/140 (2.1%)80/140 (57.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mg
Psychotic behaviourPsychiatric disorders3/1511/1450/1460/1470/140
Blood creatine phosphokinase increasedInvestigations1/1510/1450/1460/1471/140
Chest painCardiac disorders0/1510/1450/1460/1471/140
Psychotic disorderPsychiatric disorders1/1510/1450/1460/1471/140
SchizophreniaPsychiatric disorders1/1511/1450/1461/1470/140
Atrioventricular block second degreeCardiac disorders0/1511/1450/1460/1470/140
Fear of needlesPsychiatric disorders0/1511/1450/1460/1470/140
Femoral neck fractureInjury, poisoning and procedural complications0/1511/1450/1460/1470/140
Foot fractureInjury, poisoning and procedural complications0/1511/1450/1460/1470/140
Spinal compression fractureMetabolism and nutrition disorders0/1511/1450/1460/1470/140
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mg
InsomniaPsychiatric disorders11/15115/14524/14624/14721/140
Extrapyramidal disorderNervous system disorders9/15117/14514/14619/14721/140
HeadacheNervous system disorders17/15117/14511/14612/14713/140
SedationNervous system disorders6/1518/1457/14612/14716/140
ConstipationGastrointestinal disorders6/15114/1459/1468/14713/140
AkathisiaNervous system disorders8/15113/14514/14613/14712/140
SchizophreniaPsychiatric disorders12/1516/1457/1469/1471/140
NauseaGastrointestinal disorders5/1517/14511/14611/1479/140
TremorNervous system disorders6/1515/1457/1464/14710/140
VomitingGastrointestinal disorders5/1514/1459/1468/1474/140

Baseline characteristics

Safety population: All randomized participants who took at least 1 dose of double-blind investigational product.

Age, Continuous
Age, Continuous(years)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mgTotal
Mean36.0 ± 10.836.8 ± 9.637.1 ± 10.435.8 ± 10.836.5 ± 11.136.4 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mgTotal
Female5052394442227
Male1019310710398502
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mgTotal
Hispanic or Latino6724524
Not Hispanic or Latino145138144143135705
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mgTotal
American Indian or Alaska Native120003
Asian3634373937183
Native Hawaiian or Other Pacific Islander000000
Black or African American3432383235171
White8077717567370
More than one race000112
Unknown or Not Reported000000
Weight
Weight(kg)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mgTotal
Mean74.4 ± 18.671.7 ± 17.774.8 ± 16.372.4 ± 16.675.1 ± 18.273.7 ± 17.5
Height
Height(cm)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mgTotal
Mean170.8 ± 11.2169.0 ± 10.5170.7 ± 10.3170.3 ± 10.4170.0 ± 10.5170.2 ± 10.6
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mgTotal
Mean25.2 ± 4.524.9 ± 4.925.6 ± 4.624.8 ± 4.225.8 ± 4.825.2 ± 4.6
Waist circumference
Waist circumference(cm)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgCariprazine 4.5 mgRisperidone 4.0 mgTotal
Mean86.7 ± 12.985.2 ± 13.187.6 ± 12.685.8 ± 12.788.0 ± 13.086.7 ± 12.9
08

Study locations

65 sites
  • Forest Investigative Site
    Costa Mesa, California 92626, United States
  • Forest Investigative Site
    Long Beach, California 90813, United States
  • Forest Investigative Site
    Oceanside, California 92056, United States
  • Forest Investigative Site
    Paramount, California 90723, United States
  • Forest Investigative Site
    Riverside, California 92506, United States
  • Forest Investigative Site
    Washington, District of Columbia 20016, United States
  • Forest Investigative Site
    Bradenton, Florida 34208, United States
  • Forest Investigative Site
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site
    Lake Charles, Louisiana 70601, United States
  • Forest Investigative Site
    Baltimore, Maryland 21202, United States
  • Forest Investigative Site
    Flowood, Mississippi 39232, United States
  • Forest Investigative Site
    Bridgeton, Missouri 63044, United States
  • Forest Investigative Site
    Cincinnati, Ohio 45219, United States
  • Forest Investigative Site
    Charleston, South Carolina 29405, United States
  • Forest Investigative Site
    Memphis, Tennessee 28117, United States
  • Forest Investigative Site
    Houston, Texas 77008, United States
  • Forest Investigative Site
    Houston, Texas 77021, United States
  • Forest Investigative Site
    Irving, Texas 75062, United States
  • Forest Investigative Site
    Vijaywada, Andh Prad 520002, India
  • Forest Investigative Site
    Visakhapatnam, Andh Prad 530017, India
  • Forest Investigative Site
    Ahmedabad, Gujarat 380013, India
  • Forest Investigative Site
    Ahmedabad, Gujarat 380015, India
  • Forest Investigative Site
    Bangalore, Karna 560010, India
  • Forest Investigative Site
    Bangalore, Karna 560027, India
  • Forest Investigative Site
    Mangalore, Karna 574160, India
  • Forest Investigative Site
    Mangalore, Karna 575001, India
  • Forest Investigative Site
    Manipal, Karna 576104, India
  • Forest Investigative Site
    Mysore, Karna 570004, India
  • Forest Investigative Site
    Pune, Mahara 411004, India
  • Forest Investigative Site
    Jaipur, Rajasthan 302021, India
  • Forest Investigative Site
    Chennai, Tamilnadu 600003, India
  • Forest Investigative Site
    Chennai, Tamilnadu 600101, India
  • Forest Investigative Site
    Tirupati, Tamilnadu 517507, India
  • Forest Investigative Site
    Kanpur, Uttar Prad 208005, India
  • Forest Investigative Site
    Johor Bahru, Johor 80100, Malaysia
  • Forest Investigative Site
    Kota Bharu, Kelantan 15586, Malaysia
  • Forest Investigative Site
    Lembah Pantai, Kuala Lumpur 59100, Malaysia
  • Forest Investigative Site
    Ipoh, Perak 30990, Malaysia
  • Forest Investigative Site
    Ulu Kinta, Perak 31250, Malaysia
  • Forest Investigative Site
    Arkhangelsk, 163060, Russian Federation
  • Forest Investigative Site
    Gatchina, 188357, Russian Federation
  • Forest Investigative Site
    Kazan, 420012, Russian Federation
  • Forest Investigative Site 1
    Moscow, 115522, Russian Federation
  • Forest Investigative Site 2
    Moscow, 115522, Russian Federation
  • Forest Investigative Site
    Moscow, 117152, Russian Federation
  • Forest Investigative Site
    Nizhniy Novgorod, 603155, Russian Federation
  • Forest Investigative Site
    Samara, 443016, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 190005, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 190121, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 191119, Russian Federation
  • Forest Investigative Site 2
    St. Petersburg, 193019, Russian Federation
  • Forest Investigative Site1
    St. Petersburg, 193019, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 193167, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 197341, Russian Federation
  • Forest Investigative Site
    Dnipropetrovsk, Dnipropetrovsk Oblast 49616, Ukraine
  • Forest Investigative Site
    Donetsk, Donetsk Oblast 83037, Ukraine
  • Forest Investigative Site
    Kharkiv, Kharkiv Oblast 61068, Ukraine
  • Forest Investigative Site
    Glevakha, Kyiv Oblast 08630, Ukraine
  • Forest Investigative Site
    Kyiv, Kyiv Oblast 04080, Ukraine
  • Forest Investigative Site
    Kyiv, Kyiv Oblast 04655, Ukraine
  • Forest Investigative Site
    Odessa, Odessa Oblast 65006, Ukraine
  • Forest Investigative Site
    Ternopil, Ternopil Oblast 46020, Ukraine
  • Forest Investigative Site
    Chernigiv, 14000, Ukraine
  • Forest Investigative Site
    Kherson, Vil. Stepanivka, 73488, Ukraine
  • Forest Investigative Site
    Kiev, 02660, Ukraine
09

References and documents

Publications

  • Laszlovszky I, Barabassy A, Nemeth G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021 Jul;38(7):3652-3673. doi: 10.1007/s12325-021-01797-5. Epub 2021 Jun 6. PubMed 34091867 ↗
  • Barabassy A, Sebe B, Acsai K, Laszlovszky I, Szatmari B, Earley WR, Nemeth G. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatr Dis Treat. 2021 Apr 7;17:957-970. doi: 10.2147/NDT.S301225. eCollection 2021. Erratum In: Neuropsychiatr Dis Treat. 2021 May 17;17:1481. doi: 10.2147/NDT.S316858. PubMed 33854317 ↗
  • Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Nemeth G, Laszlovszky I, Szalai E, Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019 Jan;29(1):127-136. doi: 10.1016/j.euroneuro.2018.10.008. Epub 2018 Nov 20. PubMed 30470662 ↗
  • Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017 Nov;32(6):319-328. doi: 10.1097/YIC.0000000000000187. PubMed 28692485 ↗
  • Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry. 2016 Jan;77(1):109-15. doi: 10.4088/JCP.15m10192. PubMed 26845266 ↗
  • Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, Laszlovszky I. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014 Feb;152(2-3):450-7. doi: 10.1016/j.schres.2013.11.041. Epub 2014 Jan 10. PubMed 24412468 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2008 to primary completion in Aug 2009, 14 months.

Results were first posted in Jun 2019, 9 years 9 months after primary completion. A results delay was requested in Mar 2012.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 14 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2008
First posted
Jun 10, 2008
StartActual
Jun 30, 2008
Primary completionActual
Aug 31, 2009
CompletionActual
Aug 31, 2009
Results delay requested
Mar 2, 2012
Results first posted
Jun 12, 2019
Last update
Jun 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00694707
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Jun 10, 2008
Start date
Jun 30, 2008
Primary completion
Aug 31, 2009
Completion
Aug 31, 2009
Results posted
Jun 12, 2019
Last update
Jun 12, 2019

Study contacts

Suresh Durgam, MD
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion